CA2653085C - Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof - Google Patents

Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof Download PDF

Info

Publication number
CA2653085C
CA2653085C CA2653085A CA2653085A CA2653085C CA 2653085 C CA2653085 C CA 2653085C CA 2653085 A CA2653085 A CA 2653085A CA 2653085 A CA2653085 A CA 2653085A CA 2653085 C CA2653085 C CA 2653085C
Authority
CA
Canada
Prior art keywords
solution
ginsenoside
water
adjuvant
near dryness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2653085A
Other languages
English (en)
French (fr)
Other versions
CA2653085A1 (en
Inventor
Li Fu
Hong Liu
Mingming Lu
Qi Lu
Seong Tae Cho
Wanzhe Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Fusheng Natural Medicine Development Co Ltd
Original Assignee
Dalian Fusheng Natural Medicine Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Fusheng Natural Medicine Development Co Ltd filed Critical Dalian Fusheng Natural Medicine Development Co Ltd
Publication of CA2653085A1 publication Critical patent/CA2653085A1/en
Application granted granted Critical
Publication of CA2653085C publication Critical patent/CA2653085C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2653085A 2006-05-22 2007-05-18 Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof Active CA2653085C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2006100466172A CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法
CN200610046617.2 2006-05-22
PCT/CN2007/001635 WO2007134534A1 (fr) 2006-05-22 2007-05-18 Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant

Publications (2)

Publication Number Publication Date
CA2653085A1 CA2653085A1 (en) 2007-11-29
CA2653085C true CA2653085C (en) 2016-01-19

Family

ID=37581875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2653085A Active CA2653085C (en) 2006-05-22 2007-05-18 Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof

Country Status (10)

Country Link
US (2) US8487090B2 (https=)
EP (1) EP2025339B1 (https=)
JP (1) JP5525814B2 (https=)
KR (2) KR20090014300A (https=)
CN (1) CN1883492B (https=)
AU (1) AU2007252183B2 (https=)
CA (1) CA2653085C (https=)
ES (1) ES2477873T3 (https=)
RU (1) RU2432164C2 (https=)
WO (1) WO2007134534A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN101530389B (zh) * 2008-03-11 2012-02-15 沈阳市万嘉生物技术研究所 人参皂苷Rg3磷脂复合物及其制备方法
CN102091114B (zh) * 2009-12-15 2014-11-26 河北以岭医药研究院有限公司 一种中药冻干注射剂及其制备方法
KR100992800B1 (ko) * 2010-05-14 2010-11-08 주식회사 지씨에이치앤피 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법
CN103845280B (zh) * 2012-11-30 2017-04-12 富力 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途
CN103845348B (zh) * 2012-11-30 2016-07-13 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用
KR101316095B1 (ko) * 2013-01-30 2013-10-11 경희대학교 산학협력단 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물
KR102021463B1 (ko) * 2013-04-24 2019-09-16 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR101595426B1 (ko) 2013-08-30 2016-02-18 (주)녹십자웰빙 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물
CN104643058A (zh) * 2013-11-21 2015-05-27 富力 20(R)-人参皂苷Rg3在制备改善或/和治疗肝硬化疾病的药物中的应用
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
CN105012315A (zh) * 2014-04-24 2015-11-04 上海中医药大学 20(r)-原人参二醇的医药用途
CN105777838A (zh) * 2014-12-17 2016-07-20 富力 20(R)-人参皂苷Rg3衍生物、制备方法及其应用
CN105982906A (zh) * 2015-02-11 2016-10-05 富力 20(R)-人参皂苷Rg3在制备缓解或/和治疗类风湿病症的药物或保健品中的应用及药物
KR101772759B1 (ko) 2015-09-25 2017-08-30 순천향대학교 산학협력단 안정화된 무정형의 20(R)-진세노사이드 Rg3, 이의 제조방법 및 이를 함유하는 약제학적 제제
CN105878206A (zh) * 2016-03-31 2016-08-24 北京万全德众医药生物技术有限公司 一种人参皂苷Rg3的软胶囊及其制备方法
KR20180000379A (ko) * 2016-06-22 2018-01-03 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물
CN108310106A (zh) * 2018-03-30 2018-07-24 吉林省恒实传食品科技发展有限公司 一种补肾填髓、健脑益智、辅助改善记忆的中药组合物及其应用
KR20200112012A (ko) * 2019-03-20 2020-10-05 순천대학교 산학협력단 (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물
CN111686104A (zh) * 2020-07-01 2020-09-22 香港浸会大学深圳研究院 小白菊内酯、木犀草素、金圣草素和人参皂苷Rg3的新用途
CN112245443A (zh) * 2020-08-25 2021-01-22 富力 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用
CN116077442A (zh) * 2023-01-06 2023-05-09 吉林大学 一种含有人参皂苷Rg3的纳米颗粒及其制备方法和应用
KR102756809B1 (ko) * 2023-10-13 2025-01-22 표재성 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186015C (zh) 2001-01-18 2005-01-26 天津实验动物中心 用于冠心病心绞痛的中药复方口腔贴膜
CN1167734C (zh) * 2001-07-02 2004-09-22 董英杰 人参皂甙Rg3羟丙基-β-环糊精包合物及制剂和制备方法
CN1526405A (zh) * 2003-01-06 2004-09-08 山东绿叶天然药物研究开发有限公司 抗肿瘤的人参皂苷Rg3注射剂及其制备方法
CN1569012A (zh) * 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用
CN1569011A (zh) 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20（R）－人参皂苷－Rg3在制备治疗或预防心脑血管疾病的药物中的应用
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER

Also Published As

Publication number Publication date
EP2025339A1 (en) 2009-02-18
RU2008150468A (ru) 2010-06-27
JP2009537572A (ja) 2009-10-29
AU2007252183B2 (en) 2013-07-11
KR20120054664A (ko) 2012-05-30
US9333215B2 (en) 2016-05-10
US20130345156A1 (en) 2013-12-26
CN1883492B (zh) 2010-07-28
CN1883492A (zh) 2006-12-27
ES2477873T3 (es) 2014-07-18
KR101221680B1 (ko) 2013-01-11
KR20090014300A (ko) 2009-02-09
JP5525814B2 (ja) 2014-06-18
AU2007252183A1 (en) 2007-11-29
US20120149656A1 (en) 2012-06-14
US8487090B2 (en) 2013-07-16
WO2007134534A1 (fr) 2007-11-29
RU2432164C2 (ru) 2011-10-27
EP2025339A4 (en) 2013-01-16
CA2653085A1 (en) 2007-11-29
EP2025339B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
CA2653085C (en) Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof
US8871253B2 (en) Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
WO2017162108A1 (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
US20110318420A1 (en) Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN104042567A (zh) 一种蛇葡萄素纳米胶束及其应用
CN104844600B (zh) 一种他达拉非化合物、及其组合物
De Melo et al. In silico and in vitro study of epiisopiloturine/hydroxypropyl-β-cyclodextrin inclusion complexes obtained by different methods
EA018636B1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
CN113197854A (zh) 一种氟康唑三元纳米胶束及其制备方法
CN104814949B (zh) 提高绿原酸生物利用度的绿原酸酰化物及应用
US20150328321A1 (en) Cabazitaxel composition
JP5774013B2 (ja) シクロデキストリンのデオキシポドフィロトキシン包接錯体、その調製法、および癌治療への使用
CN108354905A (zh) 一种稳定的穿心莲内酯固体分散体及其制备方法和制剂
CN116350612B (zh) 氯硝柳胺在治疗先天性高胰岛素性低血糖症中的应用和治疗药物
CN119264475B (zh) 一种基于含单硼酸基团分子制备水凝胶的方法及应用
CN102008494B (zh) 20(R)-人参皂苷Rg3药用水溶性中间体和冻干粉针剂及制备方法
CN120248312A (zh) 一种聚合物前药及其载tpp-dox纳米胶束的制备方法与应用
CN121818545A (zh) 一种包载瑞戈非尼的白蛋白制剂、药物组合物及其制备方法与应用
CN105663060A (zh) 一种去水卫矛醇脂质体冻干粉针剂及其制备方法
CN115804852A (zh) 一种叶酸修饰青藤碱人血清白蛋白纳米粒及其制备方法和应用
CN102327219B (zh) 一种埃索美拉唑镁脂质体固体制剂
US20210030714A1 (en) Compounds for use in the treatment of brain diseases
CN121987586A (zh) 负载姜黄素的靶向细胞膜衍生囊泡递送系统及其应用
CN119112783A (zh) 一种pH敏感型去甲斑蝥素固体自微乳及其制备方法和应用
CN108721209A (zh) 一种兽用阿奇霉素注射剂

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260212